Published in Medical Letter on the CDC and FDA, September 28th, 2008
Xyzal(R) is indicated for the treatment of indoor and outdoor allergies. It is estimated that it has annual sales of approximately $200 million dollars growing at 15% per year, according to data provided by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA